The Great Rebrand: Goodbye PCOS, Hello PMOS

For decades, PCOS, polycystic ovary syndrome, has had a naming problem.

The condition affects more than 170 million women worldwide, yet its name has often made it sound like the ovaries are simply full of cysts. They are not. In fact, the term “polycystic” can be misleading because the ovarian appearance seen in some patients usually reflects multiple small follicles, not pathological cysts. And not everyone with the condition has this ovarian appearance.

Now, there has been a major scientific rebrand.

In 2026, an international consensus process involving patients, healthcare professionals, and 56 organisations agreed on a new name: Polyendocrine Metabolic Ovarian Syndrome (PMOS). The goal is not to create a new disease, but to give the existing condition a name that better reflects what we now understand about its biology.

So, what happened to the “cysts”?

They were never really the main story. The condition is much more than an ovarian problem. It involves interactions between reproductive hormones, metabolism, insulin regulation, and other endocrine pathways. Symptoms can include irregular menstrual cycles, excess androgen activity, acne, unwanted hair growth, fertility difficulties, and metabolic complications.

That is where the new name comes in. Polyendocrine highlights the involvement of multiple hormonal pathways.  Metabolic recognizes the important relationship with metabolic health. Ovarian keeps the reproductive and ovarian features in the picture. In other words, the new name tries to describe the whole biological puzzle, rather than putting the spotlight on one ultrasound finding. And this is more than a cosmetic name change.

The change also reminds us why diagnosis and management should look beyond the ovaries. Someone with PMOS may need attention not only to menstrual and reproductive health, but also to metabolic risk, cardiovascular health, psychological well-being, and long-term lifestyle factors.

Treatment, therefore, is not a one-size-fits-all prescription. Depending on the individual's symptoms and goals, management may include lifestyle interventions, menstrual-cycle regulation, treatment of hyperandrogenic symptoms, fertility treatment, and metabolic therapies such as metformin when clinically appropriate.

So, goodbye to the idea that this is simply a condition of “polycystic ovaries.” Hello to a more complete picture.

PMOS is essentially the same condition we knew as PCOS—but with a name that finally tries to tell the whole story. And perhaps the ovaries can finally stop taking all the blame.